Editorial
Pembrolizumab for advanced hepatocellular carcinoma: tunnel at the end of the light
Abstract
Advanced hepatocellular carcinoma (HCC) is a dreary disease with limited therapeutic options and targeted therapy with sorafenib or regorafenib remain the only standard systemic treatment. These, however have modest efficacy at the expense of associated toxicity (1,2).
